Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure

Keyphrases

• Airway Eosinophilia 16%
• Airway Hyperresponsiveness 50%
• Allergen 16%
• Allergic Asthma 16%
• Antigen Exposure 100%
• Antigen-specific 33%
• Asthma Symptoms 16%
• Atopic Asthma 16%
• Bronchoalveolar Lavage 33%
• Chronic Airway Inflammation 16%
• Chronic Asthma 100%
• CpG DNA 50%
• CpG ODN 100%
• DNA Oligonucleotides 16%
• Egg Antigen 16%
• Enhanced Release 16%
• Eosinophilia 16%
• Goblet Cell Hyperplasia 16%
• Inflammation Markers 16%
• Inhalation 16%
• Inhalation Challenge 16%
• Inhaled Allergens 16%
• Interleukin-10 33%
• Interleukin-13 (IL-13) 16%
• Interleukin-4 (IL-4) 16%
• Interleukin-5 (IL-5) 16%
• Mucosal Administration 33%
• Mucosal Immunotherapy 100%
• Murine Model 100%
• Novel Form 16%
• Ovalbumin 100%
• Recall Response 16%
• Schistosome Egg 33%
• Specific Antigen 16%
• Splenocytes 33%
• Th2 Cytokines 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Allergen 28%
• Allergic Asthma 28%
• Asthma 100%
• Cell Hyperplasia 14%
• CpG Oligodeoxynucleotide 100%
• Cytokine 14%
• Eosinophilia 28%
• Immunotherapy 100%
• Inflammation 14%
• Interleukin 10 28%
• Interleukin 13 14%
• Interleukin 4 14%
• Interleukin 5 14%
• Oligonucleotide 14%
• Ovalbumin 85%
• Respiratory Tract Allergy 42%
• Respiratory Tract Inflammation 14%
• Schistosoma 28%

Immunology and Microbiology

• Airway 28%
• Allergen 28%
• Allergic Asthma 28%
• Antigen Specificity 42%
• Asthma 100%
• CpG Oligodeoxynucleotide 100%
• Cytokine 14%
• Goblet Cell 14%
• Immunotherapy 100%
• Interleukin 10 28%
• Interleukin 13 14%
• Interleukin 4 14%
• Interleukin 5 14%
• Respiratory Tract Allergy 42%
• Schistosoma 28%
• Splenocyte 28%